Anna P Andreou

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5749937/publications.pdf

Version: 2024-02-01

50	2,185	304701	233409
papers	citations	22 h-index	45 g-index

55	55	55	2311
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study. Journal of Headache and Pain, 2022, 23, 38.	6.0	18
2	Position Paper on Post-Traumatic Headache: The Relationship Between Head Trauma, Stress Disorder, and Migraine. Pain and Therapy, 2021, 10, 1-13.	3.2	19
3	Double-Binding Botulinum Molecule with Reduced Muscle Paralysis: Evaluation in In Vitro and In Vivo Models of Migraine. Neurotherapeutics, 2021, 18, 556-568.	4.4	8
4	Noninvasive Neuromodulation in Headache: An Update. Neurology India, 2021, 69, 183.	0.4	1
5	Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study. Pain and Therapy, 2021, 10, 637-650.	3.2	12
6	Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients. Pain and Therapy, 2021, 10, 1605-1618.	3.2	8
7	Differential actions of indomethacin: clinical relevance in headache. Pain, 2021, 162, 591-599.	4.2	17
8	Cortical Mechanisms of Single-Pulse Transcranial Magnetic Stimulation in Migraine. Neurotherapeutics, 2020, 17, 1973-1987.	4.4	14
9	Sudden Caffeine Withdrawal Triggers Migraineâ€"A Randomized Controlled Trial. Frontiers in Neurology, 2020, 11, 1002.	2.4	10
10	The role of erenumab in the treatment of migraine. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642092711.	3.5	22
11	A prospective real-world analysis of erenumab in refractory chronic migraine. Journal of Headache and Pain, 2020, 21, 61.	6.0	127
12	The fifth cranial nerve in headaches. Journal of Headache and Pain, 2020, 21, 65.	6.0	81
13	Trigeminal Mechanisms of Nociception. Headache, 2020, , 3-31.	0.4	0
14	Primary headaches during lifespan. Journal of Headache and Pain, 2019, 20, 35.	6.0	71
15	Caffeine and Primary (Migraine) Headachesâ€"Friend or Foe?. Frontiers in Neurology, 2019, 10, 1275.	2.4	25
16	Mechanisms of migraine as a chronic evolutive condition. Journal of Headache and Pain, 2019, 20, 117.	6.0	137
17	Prospective realâ€world analysis of OnabotulinumtoxinA in chronic migraine postâ€National Institute for Health and Care Excellence UK technology appraisal. European Journal of Neurology, 2018, 25, 1069.	3.3	39
18	Non-invasive vagus nerve stimulation for the management of refractory primary chronic headaches: A real-world experience. Cephalalgia, 2018, 38, 1276-1285.	3.9	34

#	Article	IF	Citations
19	Emerging drugs for migraine treatment: an update. Expert Opinion on Emerging Drugs, 2018, 23, 301-318.	2.4	44
20	Phosphorylated Histone 3 at Serine 10 Identifies Activated Spinal Neurons and Contributes to the Development of Tissue Injury-Associated Pain. Scientific Reports, 2017, 7, 41221.	3.3	11
21	Tackling the perils of unawareness: the cluster headache case. Journal of Headache and Pain, 2017, 18, 49.	6.0	4
22	Pharmacology of reflex blinks in the rat: a novel model for headache research. Journal of Headache and Pain, 2016, 17, 96.	6.0	3
23	Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine. Brain, 2016, 139, 2002-2014.	7.6	105
24	Protective Effects of Non-Anticoagulant Activated Protein C Variant (D36A/L38D/A39V) in a Murine Model of Ischaemic Stroke. PLoS ONE, 2015, 10, e0122410.	2.5	12
25	Divergence from the classical hydroboration reactivity; boron containing materials through a hydroboration cascade of small cyclic dienes. Chemical Science, 2015, 6, 6262-6269.	7.4	8
26	Modulation of nociceptive dural input to the trigeminocervical complex through GluK1 kainate receptors. Pain, 2015, 156, 439-450.	4.2	22
27	Evidence for orexinergic mechanisms in migraine. Neurobiology of Disease, 2015, 74, 137-143.	4.4	71
28	Animal Models of Migraine. Headache, 2015, , 31-66.	0.4	1
29	EHMTI-0237. The A11 hypothalamic nucleus is susceptible to nitric oxide signalling. Journal of Headache and Pain, 2014, 15, .	6.0	3
30	Transient receptor potential ion channels in primary sensory neurons as targets for novel analgesics. British Journal of Pharmacology, 2014, 171, 2508-2527.	5.4	76
31	Differential trigeminovascular nociceptive responses in the thalamus in the familial hemiplegic migraine 1 knock-in mouse: A Fos protein study. Neurobiology of Disease, 2014, 64, 1-7.	4.4	21
32	Anandamide produced by Ca2+-insensitive enzymes induces excitation in primary sensory neurons. Pflugers Archiv European Journal of Physiology, 2014, 466, 1421-1435.	2.8	15
33	Prevalence of migraine headache and its weight on neurological burden in Africa: A 43-year systematic review and meta-analysis of community-based studies. Journal of the Neurological Sciences, 2014, 342, 1-15.	0.6	36
34	Pharmacology of the Capsaicin Receptor, Transient Receptor Potential Vanilloid Type-1 Ion Channel. , 2014, 68, 39-76.		44
35	GABAA receptors in the nucleus raphe magnus modulate firing of neurons in the trigeminocervical complex. Journal of Headache and Pain, 2013, 14, .	6.0	4
36	Cortical modulation of thalamic function during cortical spreading depression- Unraveling a new central mechanism involved in migraine aura". Journal of Headache and Pain, 2013, 14, .	6.0	12

#	Article	IF	Citations
37	Assessing the risk of central post-stroke pain of thalamic origin by lesion mapping. Brain, 2012, 135, 2536-2545.	7.6	101
38	Acidâ€sensing ion channel 1: A novel therapeutic target for migraine with aura. Annals of Neurology, 2012, 72, 559-563.	5.3	95
39	Olvanil acts on transient receptor potential vanilloid channel 1 and cannabinoid receptors to modulate neuronal transmission in the trigeminovascular system. Pain, 2012, 153, 2226-2232.	4.2	17
40	Thrombomodulin analogues for the treatment of ischemic stroke. Journal of Thrombosis and Haemostasis, 2011, 9, 1171-1173.	3.8	4
41	Immunohistochemical characterization of calcitonin gene-related peptide in the trigeminal system of the familial hemiplegic migraine 1 knock-in mouse. Cephalalgia, 2011, 31, 1368-1380.	3.9	30
42	Topiramate in the treatment of migraine: A kainate (glutamate) receptor antagonist within the trigeminothalamic pathway. Cephalalgia, 2011, 31, 1343-1358.	3.9	76
43	A potential nitrergic mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches. Journal of Headache and Pain, 2010, 11, 477-483.	6.0	66
44	GABA and valproate modulate trigeminovascular nociceptive transmission in the thalamus. Neurobiology of Disease, 2010, 37, 314-323.	4.4	63
45	Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain, 2010, 133, 2540-2548.	7.6	99
46	Animal models of headache: from bedside to bench and back to bedside. Expert Review of Neurotherapeutics, 2010, 10, 389-411.	2.8	58
47	Therapeutic potential of novel glutamate receptor antagonists in migraine. Expert Opinion on Investigational Drugs, 2009, 18, 789-803.	4.1	65
48	Activation of iGluR5 kainate receptors inhibits neurogenic dural vasodilatation in an animal model of trigeminovascular activation. British Journal of Pharmacology, 2009, 157, 464-473.	5.4	41
49	Neurobiology of migraine. Neuroscience, 2009, 161, 327-341.	2.3	318
50	Assessing the effects of three dental impression materials on the isolated sciatic nerve of rat and frog. Toxicology in Vitro, 2007, 21, 103-108.	2.4	12